Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
Keywords:
Hepatocellular carcinoma
Cytochrome P450
Sorafenib
EET
EDP
Omega-3 fatty acids
Oxylipins
Lipidomics
Note:
This is an openaccess article distributed under the terms
of the Creative Commons Attribution
License (CC BY). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.
Citation:
Leineweber, C. G.; Rabehl, M.; Pietzner, A.; et al. "Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma". Frontiers In Pharmacology. 14, 2023, 1124214
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.